society power

Two Drug Prices at Once

What happened

The Trump administration is pursuing two contradictory drug pricing strategies simultaneously. On one side: a proposed 100% tariff on brand-name pharmaceuticals imported from companies that have not struck individual pricing deals with the president, justified as a national security measure to push manufacturing onshore. On the other: the CMS just added 15 more high-cost drugs to Medicare's negotiation program, continuing the IRA-era framework that allows the government to set prices directly. The tariff is punitive and designed to compel pharmaceutical companies to lower prices or face import duties. The Medicare negotiation is administrative and set prices through a government-to-manufacturer process. Both are aimed at the same problem. They use opposite mechanisms and create opposite incentives for manufacturers.

Trump is running a protection racket and a price-control program at the same time, and they are designed to reward different sets of companies for different kinds of compliance.

The Hidden Bet

The 100% pharmaceutical tariff would actually lower drug prices in the United States.

A 100% tariff on imported brand-name drugs raises the cost of those drugs for US distributors and insurers, which then passes through to consumers unless manufacturers absorb the entire tariff by lowering their US list prices. There is no economic mechanism by which a tariff on imports forces a price cut; it creates a choice between paying the tariff, manufacturing domestically, or striking an individual deal with Trump. The first option raises prices. The second takes years. The third is not a market mechanism, it is a negotiation with one buyer.

The Medicare negotiation program and the tariff threat are coordinated policy.

Medicare negotiation was established under the IRA in 2022 and is being administered by CMS on a statutory timeline. The tariff is a White House executive action. They are not designed together and may create directly conflicting signals: a drug company that agreed to a Medicare price deal in 2025 now faces a tariff threat that applies to companies that have not struck deals with Trump personally. It is not clear whether the Medicare deal counts as a Trump deal or not.

Onshoring pharmaceutical manufacturing is achievable within the policy timeline being discussed.

Building a compliant pharmaceutical manufacturing facility in the United States takes 5-10 years and requires FDA approval processes that cannot be accelerated by presidential action. The companies being threatened with 100% tariffs cannot respond by onshoring in time to avoid the tariff. The tariff is therefore either a revenue measure or a negotiating lever, not a manufacturing policy.

The Real Disagreement

The real fork is whether drug pricing reform should work through government negotiating power, the way Medicare expansion does, or through trade threats that coerce individual deals with the White House, the way the tariff does. The first is a system. The second is a relationship. Systems produce predictable prices for everyone. Relationships produce better prices for whoever is in the room. Democrats favor the system; the current administration favors the relationship. The contradiction between the two strategies is not an oversight; it is the natural result of one person trying to claim credit for two incompatible approaches at once. The Medicare expansion is the only one with real downward price pressure built in. The tariff is leverage for deals that may or may not materialize.

What No One Is Saying

The 100% tariff proposal creates direct financial incentives for pharmaceutical companies to pay for access to a White House deal rather than to actually lower prices. The mechanism is: strike a deal with the president, get tariff exemption, continue charging whatever the market will bear domestically. This is not drug pricing reform. It is pharmaceutical companies paying rent to avoid a punitive tariff while consumers see no change.

Who Pays

Generic drug manufacturers in India and Eastern Europe

If tariff takes effect July 31 as proposed

The tariff appears targeted at brand-name manufacturers, but the regulatory language is broad enough to capture generics that are manufactured abroad. If generics face tariffs, the primary beneficiaries of cheap pharmaceutical competition in the US disappear.

Patients in countries with subsidized drug pricing (Australia, UK, EU)

Trade negotiations currently underway

Trump's MFN pricing condition means the US wants to pay no more than the lowest price any comparable country pays. If accepted, manufacturers would need to raise prices in Australia and Europe to avoid lowering US prices to that level. Australia has already indicated it will not compromise its PBS to satisfy the MFN condition.

US consumers on brand-name drugs not covered by Medicare negotiation

Immediate if tariffs take effect; no relief timeline without expanded negotiation

The 15 Medicare-negotiated drugs affect a specific set of patients. The tens of millions of Americans on brand-name drugs not yet on the negotiation list receive no price relief from either policy, and may see prices rise if manufacturers pass tariff costs through distribution channels.

Scenarios

Deal machine

Major European and Japanese pharmaceutical companies negotiate individual deals with the White House, accepting modest price reductions in exchange for tariff exemption. Tariff never fully takes effect. Medicare negotiations expand slowly. Drug prices fall marginally for select products.

Signal Pharma executives visiting the White House within 60 days of tariff announcement and deals announced via executive press release.

Tariff takes hold

Several large manufacturers refuse to negotiate and face the 100% tariff on July 31. Prices for affected drugs rise 30-50% as distributors absorb partial costs. Congress intervenes with emergency legislation capping insulin and diabetes drugs, but the broader tariff stands.

Signal No major pharma deal announcements by June 15 and no court injunction blocking the July 31 effective date.

Court blocks the tariff

A federal court issues a preliminary injunction against the pharmaceutical tariff, finding insufficient statutory authority under the national security framework used to justify it, consistent with the pattern of IEEPA and Section 122 rulings. The tariff never takes effect. Medicare negotiations continue as the only active price mechanism.

Signal A federal judge issuing a TRO within 30 days of tariff rule publication, with plaintiffs including foreign manufacturers and US hospital systems.

What Would Change This

Evidence that the White House is coordinating the tariff threat with the Medicare negotiation program through a joint policy framework, rather than running them on parallel tracks from different agencies, would suggest a coherent strategy. Right now the absence of any such coordination framework is the most important signal that the tariff is leverage rather than policy.